280 related articles for article (PubMed ID: 16148547)
1. Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland.
Murphy SJ; Dickey W; Hughes D; O'Connor FA
Eur J Gastroenterol Hepatol; 2005 Oct; 17(10):1029-35. PubMed ID: 16148547
[TBL] [Abstract][Full Text] [Related]
2. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
3. A surveillance programme for Barrett's oesophagus in a UK general hospital.
Olithselvan A; Gorard DA; McIntyre AS
Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
[TBL] [Abstract][Full Text] [Related]
4. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?
Kunzmann AT; Coleman HG; Johnston BT; Turkington RC; McManus D; Anderson LA; Thrift AP
Dig Dis Sci; 2021 Jun; 66(6):1965-1973. PubMed ID: 32734400
[TBL] [Abstract][Full Text] [Related]
5. Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance.
Rana PS; Johnston DA
Dis Esophagus; 2000; 13(1):28-31. PubMed ID: 11005328
[TBL] [Abstract][Full Text] [Related]
6. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.
Bhat S; Coleman HG; Yousef F; Johnston BT; McManus DT; Gavin AT; Murray LJ
J Natl Cancer Inst; 2011 Jul; 103(13):1049-57. PubMed ID: 21680910
[TBL] [Abstract][Full Text] [Related]
7. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only--what is the clinical significance?
Meining A; Ott R; Becker I; Hahn S; Mühlen J; Werner M; Höfler H; Classen M; Heldwein W; Rösch T
Gut; 2004 Oct; 53(10):1402-7. PubMed ID: 15361485
[TBL] [Abstract][Full Text] [Related]
8. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study.
de Jonge PJ; van Blankenstein M; Looman CW; Casparie MK; Meijer GA; Kuipers EJ
Gut; 2010 Aug; 59(8):1030-6. PubMed ID: 20639249
[TBL] [Abstract][Full Text] [Related]
9. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
O'Connor JB; Falk GW; Richter JE
Am J Gastroenterol; 1999 Aug; 94(8):2037-42. PubMed ID: 10445525
[TBL] [Abstract][Full Text] [Related]
10. Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival.
Aldulaimi DM; Cox M; Nwokolo CU; Loft DE
Eur J Gastroenterol Hepatol; 2005 Sep; 17(9):943-50. PubMed ID: 16093872
[TBL] [Abstract][Full Text] [Related]
11. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance.
Gudlaugsdottir S; van Blankenstein M; Dees J; Wilson JH
Eur J Gastroenterol Hepatol; 2001 Jun; 13(6):639-45. PubMed ID: 11434588
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. Gruppo Operativo per lo Studio delle Precancerosi Esofagee (GOSPE).
Ferraris R; Bonelli L; Conio M; Fracchia M; Lapertosa G; Aste H
Eur J Gastroenterol Hepatol; 1997 Sep; 9(9):881-5. PubMed ID: 9355787
[TBL] [Abstract][Full Text] [Related]
13. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
14. Barrett's oesophagus: an audit of surveillance over a 17-year period.
Gladman L; Chapman W; Iqbal TH; Gearty JC; Cooper BT
Eur J Gastroenterol Hepatol; 2006 Mar; 18(3):271-6. PubMed ID: 16462540
[TBL] [Abstract][Full Text] [Related]
15. Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma.
Hillman LC; Chiragakis L; Clarke AC; Kaushik SP; Kaye GL
J Gastroenterol Hepatol; 2003 May; 18(5):526-33. PubMed ID: 12702044
[TBL] [Abstract][Full Text] [Related]
16. Increased detection rates of Barrett's oesophagus without rise in incidence of oesophageal adenocarcinoma.
Hurschler D; Borovicka J; Neuweiler J; Oehlschlegel C; Sagmeister M; Meyenberger C; Schmid U
Swiss Med Wkly; 2003 Sep; 133(37-38):507-14. PubMed ID: 14652799
[TBL] [Abstract][Full Text] [Related]
17. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R; O'Sullivan K; Quigley EM
Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
[TBL] [Abstract][Full Text] [Related]
18. Audit of a Barrett's epithelium surveillance database.
Basu KK; Pick B; de Caestecker JS
Eur J Gastroenterol Hepatol; 2004 Feb; 16(2):171-5. PubMed ID: 15075990
[TBL] [Abstract][Full Text] [Related]
19. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study.
Macdonald CE; Wicks AC; Playford RJ
BMJ; 2000 Nov; 321(7271):1252-5. PubMed ID: 11082084
[TBL] [Abstract][Full Text] [Related]
20. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
